Literature DB >> 25006052

Modified Valsalva manoeuvre to treat recurrent supraventricular tachycardia: description of the technique and its successful use in a patient with a previous near fatal complication of DC cardioversion.

Andrew Appelboam1, James Gagg2, Adam Reuben1.   

Abstract

Patients with attacks of re-entrant supraventricular tachycardia (SVT) frequently present to the emergency department (ED). The Valsalva manoeuvre (VM) is the most effective and safe vagal manoeuvre and advocated as the first-line treatment in stable patients but has a relatively low cardioversion success rate. Improving its efficacy would reduce patients' exposure to the side effects and complications of second-line treatments and has other potential benefits. We describe a modification to the VM, which is currently being studied, and present the case of a 23-year-old patient who was successfully treated with this modified VM after a previous near-fatal complication of direct current (DC) cardioversion. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25006052      PMCID: PMC4091469          DOI: 10.1136/bcr-2013-202699

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Vagal response varies with Valsalva maneuver technique: a repeated-measures clinical trial in healthy subjects.

Authors:  Lu Fee Wong; David M Taylor; Michael Bailey
Journal:  Ann Emerg Med       Date:  2004-04       Impact factor: 5.721

Review 2.  The Valsalva manoeuvre--cardiovascular effects and performance technique: a critical review.

Authors:  Robert Looga
Journal:  Respir Physiol Neurobiol       Date:  2005-05-12       Impact factor: 1.931

3.  Augmented Valsalva maneuver for supraventricular tachycardia in the young.

Authors:  J F Chance; J G Warner; T Elsawy
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

4.  The 10 mL syringe is useful in generating the recommended standard of 40 mmHg intrathoracic pressure for the Valsalva manoeuvre.

Authors:  Gavin Smith; Malcolm J Boyle
Journal:  Emerg Med Australas       Date:  2009-12       Impact factor: 2.151

5.  Modified Valsalva maneuver for paroxysmal supraventricular tachycardia.

Authors:  A Torren
Journal:  Cardiovasc Drugs Ther       Date:  1997-03       Impact factor: 3.727

6.  Impact of a modified Valsalva manoeuvre in the termination of paroxysmal supraventricular tachycardia.

Authors:  S Walker; P Cutting
Journal:  Emerg Med J       Date:  2010-04       Impact factor: 2.740

Review 7.  Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia.

Authors:  Gavin D Smith; Kylie Dyson; David Taylor; Amee Morgans; Kate Cantwell
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

Review 8.  Review article: Adenosine use in the emergency department.

Authors:  James A Innes
Journal:  Emerg Med Australas       Date:  2008-06       Impact factor: 2.151

9.  Randomised Evaluation of modified Valsalva Effectiveness in Re-entrant Tachycardias (REVERT) study.

Authors:  Andrew Appelboam; Adam Reuben; Clifford Mann; Trudie Lobban; Paul Ewings; Jonathan Benger; Jane Vickery; Andrew Barton; James Gagg
Journal:  BMJ Open       Date:  2014-03-12       Impact factor: 2.692

  9 in total
  2 in total

1.  Prehospital conversion of paroxysmal supraventricular tachycardia using the modified Valsalva maneuver: A case report.

Authors:  Padarath Gangaram; Yugan Pillay; Bernard Christopher Pillay; Guillaume Alinier
Journal:  Qatar Med J       Date:  2020-11-27

2.  Randomised Evaluation of modified Valsalva Effectiveness in Re-entrant Tachycardias (REVERT) study.

Authors:  Andrew Appelboam; Adam Reuben; Clifford Mann; Trudie Lobban; Paul Ewings; Jonathan Benger; Jane Vickery; Andrew Barton; James Gagg
Journal:  BMJ Open       Date:  2014-03-12       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.